$56.53 -0.79 (-1.38%)
12/3/2009 4:00 PM

Celgene Corp (CELG)

CAPS Rating: 4 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Recs

0
Member Avatar ypcheng (< 20) Submitted: 2/25/2008 10:34:36 AM : Outperform Start Price: $56.09 CELG Score: +9.74

In light of the approval of Avastin by FDA to Genetech, I believe this company will gets its approvals of its rich pipeline and its stock should go up.

Report this Post 0 Comments

Featured Broker Partners